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Dendritic cells (DCs) are one type of important inflammatory cells in the pathogenesis
of asthma for early response to allergen exposure.  Monocyte-derived DCs (MoDCs)
are characterized by a high antigen uptake capacity and poor T-cell stimulatory activity,
both features of immature DCs.  By stimulation with tumor necrosis factor- a  (TNF- a )
or antigen capture, these cells differentiate into mature DCs with the disappearance of
antigen-capturing regions, and increase in stimulatory activity.  We measured the expres-
sion of some molecules on MoDCs before and after stimulation with TNF- a  or house
dust mite (HDM) antigen, from 9 house dust mite (HDM)-allergic asthmatic patients
and 8 normal control subjects by flow cytometry.  Primary MoDCs from HDM-allergic
asthmatics showed a greater expression of histocompatibility leukocyte antigen (HLA)-
DR and mannose receptor (MR), but not of CD80, CD86 or intercellular adhesion
molecule-1 (ICAM-1), than those from normal subjects (P < 0.05).  After stimulation
with TNF- a  or HDM, DCs from asthmatic patients showed a greater expression of
HLA-DR, CD86 and ICAM-1, than those from normal subjects.  In HDM-allergic
asthmatic patients, MR expression on DCs significantly declined after stimulation by
HDM compared with stimulation by TNF-a  (P < 0.05).  Results suggest that the reduction
of MR expression may be characteristic on mature DCs after HDM exposure in allergic
asthma.
Key words:  asthma; dendritic cells; histocompatibility leukocyte antigen-deoxyribose; house dust
mite; mannose receptor
Abbreviations:  DC, dendritic cell; FEV1.0, forced expiratory volume in one second; FITC, fluorescein
isothiocyanate; GM-CSF, granulocyte-macrophage colony-stimulating factor; HDM, house dust mite; HLA,
histocompatibility leukocyte antigen; ICAM-1, intercellular adhesion molecule-1; IgE, immunoglobulin E;
IL-4, interleukin-4; MHC, major histocompatibility complex; MoDC, monocyte-derived dendritic cell; MR,
mannose receptor; PBMC, peripheral blood mononuclear cell; PBS, phosphate buffered saline; TNF-a , tumor
necrosis factor-a
Allergic asthma is a chronic inflammatory
disease characterized by increased infiltration
of eosinophils and allergen-specific Th2 lym-
phocytes into the airways (Lundgren et al.,
1988; Ackerman et al., 1994).  It is generally
accepted that airway dendritic cells (DCs) are
essential for stimulating naive T cells in a pri-
mary immune response to inhaled antigens and
the most prominent cells involved in the
presentation of inhaled antigens to Th2 lympho-
cytes (Ackerman et al., 1994; Bellini et al.,
1993; Inaba et al., 1990).   DCs are present in
the bronchial mucosa of both normal and asth-
matic subjects.  As assessed by immunohisto-
chemistry, the airways of atopic asthmatics are
known to contain increased numbers of CD1a +
DCs (Moller et al., 1996).
The DC population in the airway epithelium
is renewed every 48 to 72 h; a more rapid
turnover reveals that DCs originate in the bone
marrow and supposedly belong to the monocyte
lineage (Holt et al., 1994; McWilliam et al.,
1995).  Romani and colleagues (1994) recently
demonstrated that monocyte-enriched periph-
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eral blood mononuclear cells (PBMCs) cultured
with granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF) and interleukin (IL)-4 can
differentiate into DCs (MoDCs).
van den Heuvel and colleagues (1998) re-
ported that MoDCs from allergic asthmatics
showed phenotypic differences in the expres-
sion of surface markers.  MoDCs have many of
the same features as immature DCs, including
the expression of molecules that enhance anti-
gen capture and weak T-cell stimulation.  If
MoDCs are stimulated by tumor necrosis factor- a
(TNF- a ) or antigens, these cells differentiate
into mature cells with the disappearance of
antigen-capturing regions and an increase in T-
cell stimulatory function (Palucka et al., 1998).
It has not been reported whether MoDCs from
asthmatics develop into mature phenotypes
after stimulation with any antigens.
The mannose receptor (MR) is a surface
175-kD C-type lectin and a membrane lectin or
sugar-specific receptor, expressed by macro-
phages and DCs (Avrameas et al., 1996;
Koning, 1997).  MR enhances a histocompatibili-
ty leukocyte antigen (HLA) class II-restricted
antigen presentation and specifically mediates
the binding and endocytosis of mannose- and
fucose-terminated glycoproteins, which are
involved in the phagocytosis of pathogens such
as the house dust mite (HDM) (Mitra and
Chatterjee, 1990), because HDM is a complex
of a glycoprotein with a high-mannose type of
oligosaccharide (Uhlir, 1993).
In this study, we examined the expression of
mature markers and T cell co-stimulating mole-
cules on MoDCs isolated from asthmatics after
stimulation with TNF- a  or HDM.
Materials and methods
Subjects
Nine asthmatic patients (6 males and 3 females)
aged 16 to 37 years (mean, 26 years) were
studied (Table 1).  Patients with asthma were
defined as having a previous history of episodic
wheezing and reversible airway obstruction,
characterized by an increase in a forced expira-
tory volume in one second (FEV1.0) of >15%
after inhalation of 40 m g of procaterol.  All pa-
tients were HDM-allergic, defined by a > 2-mm
wheal response to HDM extract (Torii, Tokyo,
Japan), and a raised serum concentration of
total immunoglobulin E (IgE > 250 IU/mL) or
specific IgE for HDM.  None of the patients re-
ceived oral corticosteroids within the 3 months
preceding the study.  Six of the asthmatic sub-
jects were taking regular inhaled corticosteroids
(range, 300 to 600 m g of beclomethasone per
day).  Patients were excluded from the study if
they experienced an asthmatic attack during the
2 months preceding the study.  Eight healthy
volunteers (mean age, 26.4 years; range, 21 to
35 years), who were HDM-non-allergic and had
no history of asthma or allergic diseases, were
Table 1.  Patients Characteristics
Patient Sex Age Total serum FEV1.0 Minimum Inhaled
number (year) IgE (% pre- dose of beclomethasone
(IU/mL) dicted) methacholine (U) (m g/day)
1 Male 16 4300 80.9 3.387 —
2 Male 23 289 84.5 0.206 400
3 Male 24 1045 91.5 1.045 400
4 Male 30 11200 79.6 0.049 300
5 Male 34 170 89.3 1.358 —
6 Male 37 246 74.1 0.439 —
7 Female 19 2650 82.5 2.13 600
8 Female 22 6060 77.2 0.459 600
9 Female 26 1125 70.1   ND 600
FEV1.0, forced expiratory volume in one second; IgE, immunoglobulin E; ND, not done.
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studied as a control group.  All participating
subjects were non-smokers and had no history
suggesting a viral respiratory tract infection
within 4 weeks preceding or during the study.
All subjects gave their informed consent.
Determination of airway responsiveness
Airway response was measured directly by
examining the dose-response curve of respira-
tory resistance drawn by an Astograph (Chest,
Tokyo) (Takishima et al., 1981) during conti-
nuous inhalation of methacholine administered
in a stepwise incremental fashion.  Briefly,
methacholine aerosol in doubling concentra-
tions (0.049–100 mg/mL) was inhaled continu-
ously through the mouth during tidal breathing
for each concentration.  The aerosol was gener-
ated by a micronebulizer (Bird, Palm Springs,
CA) with an output of 0.15 mL/min, and a parti-
cle size ranging from 0.5 to 4.0 mm.  Assess-
ment of airway responsiveness was derived
from a minimum dose of methacholine needed
to increase the dose-response curve of respira-
tory resistance.
Preparation of DCs
Sixty milliliters of peripheral blood were
sampled from asthmatic patients and normal
subjects.  Peripheral blood mononuclear cells
(PBMCs) were separated by standard Ficoll-
Hypaque (specific gravity, 1.077 g/mL;
Pharmacia, Uppsala, Sweden) density gradient
centrifugation, and were washed twice with
Mg2+- and Ca2+-free phosphate buffered saline
(PBS, pH 7.4; Research Institute for Medical
Disease, Osaka, Japan).  The cells were resus-
pended in the following medium:  RPMI 1640
with 25 mmol/L HEPES and 0.3 mmol/L
glutamine (Bio Whittaker, Walkersville, MD)
containing 10% fetal calf serum (Cansera
International Inc., Rexdale, ON, Canada), 100
U/mL penicillin and 100 m g/mL streptomycin
(Bio Whittaker), and then were incubated in
culture dishes (Falcon 3002; Becton Dickinson,
San Jose, CA) at 37 ° C with 5 % CO2 for 1 h.
After non-adherent cells were decanted, DCs
were prepared according to published methods
(Romani et al., 1994).  In brief, adherent cells
(monocyte-enriched peripheral blood mono-
nuclear cells) were cultured in medium supple-
mented with 800 U/mL of  GM-CSF (Genzyme,
Cambridge, MA) and 500 U/mL of IL-4
(Genzyme).   Cells were fed every other day
(days 2, 4 and 6) with fresh culture medium
containing the same levels of GM-CSF and IL-
4.  On day 7, cells were stimulated with and with-
out 10 m g/mL of HDM extract, supported by
Torri (Tokyo) or 10 ng/mL TNF- a  (Genzyme)
for 24 h to induce maturation.  At that point, the
cells had become mostly non-adherent, and
were removed from the plate and washed twice
in RPMI 1640.  They were then counted and
analyzed.  Viability was always above 95%.
Cell yields were expressed as the number of
DCs obtained from 108 PBMCs.
Immunofluorescence staining
The expression of surface antigens on MoDCs
was determined by the binding of monoclonal
antibodies against CD1a (IgG2a; Cosmo Bio,
Tokyo, Japan), CD1c (IgG1; Cosmo Bio),
HLA-DR (IgG2a; Pharmingen, San Diego,
CA), MR (IgG1; Pharmingen), CD80 (IgM;
Serotec, Oxford, United Kingdom), CD86
(IgG1; Serotec), CD54 (IgG1; Coulter, Krefeld,
Germany), CD11b (IgG1; Leinco, Ballwin,
MO), CD83 (IgG1; Cosmo Bio), CD14 (IgG2a;
Cosmo Bio), CD16 (IgG1; Nichirei, Tokyo)
and CD3 (IgG1; Leinco) for 90 min on ice.
After the cells were washed 3 times with PBS
containing 0.1% sodium azide (PBS-azide), the
expressions of these surface molecules were
evaluated by indirect fluorescence after incuba-
tion for 30 min on ice in the dark with either
fluorescein isothiocyanate (FITC)-conjugated
antibodies (anti-IgG2a, IgG2b, IgM; Cappel,
Durham, United Kingdom) or phycoerythrin-
conjugated antibodies (anti-IgG1; Southern
Biotechnology, Birmingham, AL).  The cells
were washed 4 times with PBS-azide, and were
analyzed by flow cytometry.
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rFI of MR on MoDCs
stimulated with HDM or TNF- a
rFI of MR on
non-stimulated MoDCs
– 1   ·  100
Fig. 1.   Uniform high forward- and side-scatter
properties of MoDCs (designated G1) and lympho-
cytes (designated G2) from representative HDM-
allergic asthmatics (a).  HDM, house dust mite; G1,
large-cell population; G2, small-cell population;
MoDC, monocyte-derived dendritic cell.
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Flow cytometry
Flow cytometry was performed with 3,000 to
5,000 cells per sample by a FACS Calibur
(Becton Dickinson).  DCs were analyzed by
selective gating based on forward- and side-
scatter parameters with large cells in non-
lymphoid areas (Fig. 1).  Statistical markers
were set using isotype-matched negative con-
trols.
Statistical analysis
Statistical analysis was performed with the Stat
View 4.0 statistics package (Abacus Concepts,
Berkeley, CA) and a Power Macintosh 7200/90
(Apple Computer, Cupertino, CA).  All data are
expressed as the mean + SD.  The nonpara-
metric Mann-Whitney U test and Wilcoxon’s
signed-rank test were used for statistical
analysis of the unpaired data and paired data,
respectively.  The rate of induction of relative
fluorescence intensity of MR on MoDCs stimu-
lated with HDM or TNF- a  was calculated by
the following formula:
where rFI stands for relative fluorescence inten-
sity.
Results
Characteristics of primary MoDCs
To induce primary MoDCs, monocyte-enriched
PBMCs were cultured with GM-CSF and IL-4
for 7 days.  The cultured cells were a hetero-
geneous population containing 16 –  6% lym-
phocytes on morphology which was determined
by using May-Grünwald-Giemsa staining.
Whereas 2.9 –  1.0 ·  106 DCs were generated
from 108 PBMCs from normal subjects, 3.8 –
0.7 ·  106 DCs could be obtained from PBMC
from HDM-allergic asthmatics compared with
normal subjects (P = 0.05).
Analysis of DCs by flow cytometry
Figure 1 shows representative forward- versus
side-scatter density plots.  On both the forward-
and side-scatter, two subpopulations consisting
of a large-cell population (G1) and a small-cell
population (G2) were found in the cultured cells
with GM-CSF and IL-4 for 7 days (Fig.  1).  The
cells in the small-cell population were CD3-
positive and CD1a-negative lymphocytes.
Using gating on the large cell population, we
assessed the surface expression on DCs.  The
percentages of CD1a- or CD1c-positive cells on
gating on the large-cell population did not differ
between asthmatic patients (48.5 –  8.3% and
81.4 –  11.3%, respectively) and control sub-
jects (54.5 –  15.7% and 80.6 –  10.4%, respec-
tively).  Less than 10% of DCs gating on the
large-cell population expressed CD14.
Expression of mature markers on DCs
To characterize mature DCs, we have used pheno-
types emphasizing the presence of CD83 and
HLA-DR.  The expression of HLA-DR on pri-
mary MoDCs was significantly higher in HDM-
G1
G2
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allergic asthmatic patients than in normal
subjects (Fig. 2) (P < 0.05), but that of CD83
was not (data not shown).  The expression of
CD83 and HLA-DR (Fig. 2) was enhanced after
stimulation with TNF- a  or HDM in the same
manner with both asthmatics and control sub-
jects.
Expression of T cell co-stimulating mole-
cules on DCs
When the expression of T cell co-stimulating
molecules CD80 (B7-1), CD86 (B7-2), CD54
(ICAM-1), and CD11b (Mac-1) on primary
MoDCs was assessed by flow cytometry, these
molecules did not differ between asthmatics
and control subjects.  The expressions of CD54
and CD86 on MoDCs after stimulation with
HDM were increased in the 2 groups of sub-
jects, and the expression of these molecules on
MoDCs from asthmatics was significantly
Fig. 2.   Expression of HLA-DR as a mature marker on MoDCs of asthmatic patients and normal subjects.
Primary MoDCs were derived from plastic-adherent peripheral blood mononuclear cells with 800 U/mL GM-
CSF and 500 U/mL IL-4 for 7 days.   Mature MoDCs were obtained from primary MoDCs by the stimulation
of 10 ng/mL TNF-a  or 10 m g/mL HDM for 24 h.   The lower, middle and upper lines in the boxes represent the
25th, 50th and 75th percentiles, respectively; the lower and upper limits of the bars represent the 10th and 90th
percentiles, respectively.   HDM, house dust mite; HLA-DR, histocompatibility leukocyte antigen-DR; IL-4,
interleukin-4; GM-CSF, granulocyte-macrophage colony-stimulating factor; MoDC, monocyte-derived
dendritic cell; TNF- a , tumor necrosis factor- a .  *P < 0.05, compared with normal subjects.  **P < 0.01,
compared with normal subjects.
higher than that from control subjects (Fig. 3).
There was no remarkable change in the inten-
sity of CD80, or CD11b after stimulation with
TNF-a  or HDM in both groups.
Expression of MR on DCs
The expression of MR on primary MoDCs was
significantly higher in HDM-allergic asthmatic
patients than in normal subjects (P < 0.05).
MR expression on MoDCs from HDM-Allergic
asthmatics was significantly reduced by
stimulation with HDM as well as TNF- a  (Fig.
4).  When the rate of induction in the expression
of MR was assessed, the MR of MoDCs from
asthmatics were shown to be more reduced than
that of DCs from control subjects after stimu-
lation with HDM (P = 0.001) (median reduction
rate; asthmatic subjects, 65% and control sub-
jects, 40%).  However, after stimulation with
TNF- a , there was no significant difference
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Fig. 3.   Expression of CD54 (A) and CD86 (B) as T cell co-stimulating molecules on MoDCs of asthmatic
patients and normal subjects.  Primary MoDCs were derived from plastic-adherent peripheral blood
mononuclear cells with 800 U/mL GM-CSF and 500 U/mL IL-4 for 7 days.   Mature MoDCs were obtained
from primary MoDCs by the stimulation of 10 ng/mL TNF-a  or 10 m g/mL HDM for 24 h.   The lower, middle
and upper lines in the boxes represent the 25th, 50th and 75th percentiles, respectively; the lower and upper
limits of the bars represent the 10th and 90th percentiles, respectively.   HDM, house dust mite; IL-4,
interleukin-4; GM-CSF, granulocyte-macrophage colony-stimulating factor; MoDC, monocyte-derived den-
dritic cell; TNF- a , tumor necrosis factor- a .  *P < 0.05, compared with normal subjects.
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between the 2 groups in the rate of reduction of
MR on stimulated MoDCs (median reduction
rate; asthmatic subjects, 55% and control sub-
jects, 75%).
Discussion
We have studied the expression of surface
markers on MoDCs from HDM-allergic asth-
matics before and after stimulation with HDM
or TNF- a  in vitro.  The expressions of HLA-
DR and MR on primary MoDCs from asthmat-
ics was higher than those from normal subjects,
suggesting that these cells from asthmatics were
differentiated into more mature DCs from the
point of view of phenotypes as previously de-
monstrated (van den Heuvel et al., 1998).  In
response to HDM, MoDCs from asthmatics
showed a greater expression of HLA-DR,
ICAM-1 and B7-2 than those from normal sub-
jects.  In addition, the expression of MR on
MoDCs reduced with stimulation with HDM,
but not TNF- a  .
Fig. 4.  Expression of MR on MoDCs of asthmatic patients and normal subjects.  Primary MoDCs were
derived from plastic-adherent peripheral blood mononuclear cells with 800 U/mL GM-CSF and 500 U/mL
IL-4 for 7 days.   Mature MoDCs were obtained from primary MoDCs by the stimulation of 10 ng/mL TNF-
a  or 10 m g/mL HDM for 24 h.   The lower, middle, and upper lines in the boxes represent the 25th, 50th and
75th percentiles, respectively; the lower and upper limits of the bars represent the 10th and 90th percentiles,
respectively.   HDM, house dust mite; IL-4, interleukin-4; GM-CSF, granulocyte-macrophage colony-
stimulating factor; MoDC, monocyte-derived dendritic cell; MR, mannose receptor; TNF- a , tumor necrosis
factor- a .  *P < 0.05, compared with normal subjects.
To our knowledge this is the first study of
phenotypical analysis of MoDCs stimulated
with a specific antigen from allergic asthmatics.
It has been reported that when DCs are induced
to a mature state by TNF- a , CD40L or lipo-
polysacharide, the expression of MHC class II,
as well as co-stimulatory molecules ICAM-1 and
B7, is up-regulated (Sallusto and Lanzavecchia,
1994; Morse et al., 1997; Palucka et al., 1998).
Similarly, our data indicate that MoDCs from
asthmatic patients showed a more mature-
phenotype after stimulation with HDM than
those from normal subjects.  As to mature-
phenotypic DCs from asthmatics, 2 reasons
could be considered.  First, a mature subpopu-
lation of peripheral monocytes might affect to
be derived into mature-phenotypic DCs from
asthmatics.  We have previously shown func-
tional and phenotypic differences between
monocytes from atopic asthmatics and those
from normal subjects (Tomita et al., 1995,
1997).  Second, exogenous cytokines such as
IL-10, IL-4, GM-CSF or IL-12 might stimulate
DCs to develop into mature cells.
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In the airways, DCs are located in and just
underneath the bronchial epithelium to allow
for the uptake of inhaled antigens (Holt  et al.,
1997; van Haarst et al., 1994).  In most tissues,
DCs are present in a so-called “immature” state,
unable to stimulate T cells.  We demonstrated
that immature MoDCs from asthmatic patients
showed a higher expression of  HLA-DR than
those from normal subjects.  Furthermore, this
differentiated marker was up-regulated by
stimulation with HDM as well as TNF-a .  A re-
cent study showed that immature DCs were
active in the biosynthesis of class II MHC and
in peptide loading, but the peptide-MHC class
II complexes were recycled by accumulating in
lysosomes and reaching the cell surface.  If
these cells started to mature, the increased bio-
synthesis of class II MHC was observed which
maximizes the specific loading of antigens
(Cella et al., 1997).  So antigen presentation to
class II-restricted T cells generally requires
such newly synthesized class II MHC on ma-
ture DCs (Pinet et al., 1995).  Thus, our findings
may imply that the newly produced HLA-DR
on “mature” DCs from asthmatics stimulated
with HDM contributes to the presentation of
inhaled antigens to T cells.
Recent studies have shown that Th2 cells
play an important role in the generation of air-
way eosinophils in asthma through their ability
to produce IL-5 (Ohnishi et al., 1993; Walker et
al., 1994).  The depletion of airway DCs sup-
pressed Th2 cytokine-associated eosinophilic
airway inflammation in a mouse model with
asthma (Lambrecht et al., 1998) suggesting that
DCs might play an important role in stimulating
Th2 cells.  ICAM-1/LFA-1 (King and Katz,
1989) and B7/CD28 (Lenschow et al., 1996;
Reiser and Stadecker, 1996) interactions are
major pathways for initiating naive T cell acti-
vation.  DCs treated with TNF- a  or lipopoly-
sacharide showed increased expression of the
class II and class I molecules, B7-1 and ICAM-
1 (Sallusto et al., 1995).  Our data demonstrated
that MoDCs from asthmatics treated with TNF-
a  or HDM develop into mature DCs, which
show enhanced expression of ICAM-1 and B7-
2.  Kuchroo and colleagues (1995) reported that
B7-2 was one of the co-stimulating molecules
for signaling Th2 cells.
We also demonstrated a significant reduc-
tion in MR on MoDCs from HDM-allergic
asthmatics, after stimulation with HDM but not
with TNF- a , in spite of a lack of significant dif-
ferences in CD80, CD86 and ICAM-1 expres-
sions.  MR, which is expressed on cultured im-
mature DCs (Reis e Sousa et al., 1993; Sallusto
et al., 1995) is internalized to mediate phago-
cytosis of various microorganisms that expose
mannosylated glycoproteins (Ezekowitz et al.,
1991).  Indeed, in DCs, MR allows the uptake
and concentration of ligands such as FITC-
labeled dextran and horseradish peroxidase
(Sallusto et al., 1995).  Engering and colleagues
(1997) demonstrated that the MR pathway in
DCs was ~100-fold more efficient in presenting
antigens to T cells.  Upon the maturation of DCs
from HDM-allergic asthmatics, the uptake of
mannosylated antigens such as HDM might
play an important pathophysiological role in
atopic asthma.
We examined the surface expression on
DCs derived from peripheral blood.  Airway
DCs originate in peripheral blood monocytes
from the bone marrow (Holt et al., 1994;
McWilliam et al., 1995).  McWilliam and col-
leagues (1995) hypothesized that the location of
the development of DCs from peripheral mono-
cytes after birth may influence the pathogenesis
of immune regulated diseases such as asthma
and allergic rhinitis.  So, further studies are re-
quired to know the nature of MoDCs.
In conclusion, we have shown that imma-
ture DCs from patients with allergic asthma
exhibit increased expression of mature markers,
and more extensive development into a mature
phase after stimulation with TNF- a  or HDM.  A
reduction in MR after stimulation with HDM
characterized DCs from patients with HDM-
allergic asthma.  These observations suggest
that MR on “mature” DCs from atopic asthma
might be used to specialize in capturing HDM
antigens.
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